Photodynamic therapy with a CD276-targeted agent for enhancing tumor anti-PD-1/PD-L1 immune checkpoint inhibition

被引：0
|
作者：
Rui, Bao [1 ,2 ]
Wang, Yanpu [3 ]
Lai Jianhao [1 ,2 ]
Liu, Zhaofei [4 ]
Wang, Fan [4 ]
机构：
[1] Peking Univ, Hlth Sci Ctr, Sch Basic Med Sci, Med Isotopes Res Ctr, Beijing, Peoples R China
[2] Peking Univ, Hlth Sci Ctr, Sch Basic Med Sci, Dept Radiat Med, Beijing, Peoples R China
[3] Peking Univ, Med Isotopes Res Ctr, Beijing, Peoples R China
[4] Peking Univ, Beijing, Peoples R China
来源：
JOURNAL OF LABELLED COMPOUNDS & RADIOPHARMACEUTICALS | 2019年 / 62卷
关键词：
D O I：
暂无
中图分类号：
Q5 [生物化学];
学科分类号：
071010 ; 081704 ;
摘要：
O-75
引用
收藏
页码：S103 / S105
页数：3
相关论文
共 50 条
  • [1] Enhancing Anti-PD-1/PD-L1 Immune Checkpoint Inhibitory Cancer Therapy by CD276-Targeted Photodynamic Ablation of Tumor Cells and Tumor Vasculature
    Bao, Rui
    Wang, Yanpu
    Lai, Jianhao
    Zhu, Hua
    Zhao, Yang
    Li, Suping
    Li, Nan
    Huang, Jing
    Yang, Zhi
    Wang, Fan
    Liu, Zhaofei
    MOLECULAR PHARMACEUTICS, 2019, 16 (01) : 339 - 348
  • [2] Dermatologic complications of anti-PD-1/PD-L1 immune checkpoint antibodies
    Sibaud, Vincent
    Meyer, Nicolas
    Lamant, Laurence
    Vigarios, Emmanuelle
    Mazieres, Julien
    Delord, Jean Pierre
    CURRENT OPINION IN ONCOLOGY, 2016, 28 (04) : 254 - 263
  • [3] Pneumonitis with anti-PD-1/PD-L1 therapy
    Naidoo, J.
    Cunningham, J.
    Woo, K. M.
    Hellmann, M. D.
    Postow, M. A.
    Drilon, A. E.
    Chaft, J. E.
    Lesokhin, A. M.
    Segal, N. H.
    Callahan, M. K.
    Rudin, C. M.
    Iyriboz, T.
    Wolchok, J. D.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S103 - S103
  • [4] Immunological features of immune-related adverse events during anti-PD-1/PD-L1 immune checkpoint inhibition
    Goswami, Meghali
    Gui, Gege
    Lindblad, Katherine
    Del Rivero, Jaydira
    Marte, Jennifer
    Dagur, Pradeep
    Destefano, Christin
    Thompson, Julie
    Popescu, Bogdan
    Dillon, Laura
    Johnson, Cheryl
    Soldin, Steven
    Lai, Catherine
    Gulley, James
    Hourigan, Christopher
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7
  • [5] Immunomodulatory effects of regorafenib: Enhancing the efficacy of anti-PD-1/PD-L1 therapy
    Liu, Junjie
    Tao, Haisu
    Yuan, Tong
    Li, Jiang
    Li, Jian
    Liang, Huifang
    Huang, Zhiyong
    Zhang, Erlei
    FRONTIERS IN IMMUNOLOGY, 2022, 13
  • [6] High PD-1/PD-L1 Checkpoint Interaction Infers Tumor Selection and Therapeutic Sensitivity to Anti-PD-1/PD-L1 Treatment
    Sanchez-Magraner, Lissete
    Miles, James
    Baker, Claire L.
    Applebee, Christopher J.
    Lee, Dae-Jin
    Elsheikh, Somaia
    Lashin, Shaimaa
    Withers, Katriona
    Watts, Andrew G.
    Parry, Richard
    Edmead, Christine
    Lopez, Jose Ignacio
    Mehta, Raj
    Italiano, Antoine
    Ward, Stephen G.
    Parker, Peter J.
    Larijani, Banafshe
    CANCER RESEARCH, 2020, 80 (19) : 4244 - 4257
  • [7] Pneumonitis From Anti-PD-1/PD-L1 Therapy
    Balaji, Aanika
    Verde, Franco
    Suresh, Karthik
    Naidoo, Jarushka
    ONCOLOGY-NEW YORK, 2017, 31 (10): : 739 - +
  • [8] The anticancer immune response of anti-PD-1/PD-L1 and the genetic determinants of response to anti-PD-1/PD-L1 antibodies in cancer patients
    Sui, Xinbing
    Ma, Junhong
    Han, Weidong
    Wang, Xian
    Fang, Yong
    Li, Da
    Pan, Hongming
    Zhang, Li
    ONCOTARGET, 2015, 6 (23) : 19393 - 19404
  • [9] Parameters of Tumor Microenvironment Determine Effectiveness of Anti-PD-1/PD-L1 Therapy
    Tashireva, Liubov A.
    Muravyova, Dariya T.
    Popova, Natalya O.
    Goldberg, Victor E.
    Vtorushin, Sergey V.
    Perelmuter, Vladimir M.
    BIOCHEMISTRY-MOSCOW, 2021, 86 (11) : 1461 - 1468
  • [10] Parameters of Tumor Microenvironment Determine Effectiveness of Anti-PD-1/PD-L1 Therapy
    Liubov A. Tashireva
    Dariya T. Muravyova
    Natalya O. Popova
    Victor E. Goldberg
    Sergey V. Vtorushin
    Vladimir M. Perelmuter
    Biochemistry (Moscow), 2021, 86 : 1461 - 1468
12345